Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026

Candel Therapeutics, Inc.

Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.
Cash and equivalents $194.8M as of March 31, 2026, expected to fund operations into Q1 2028.
Plans to submit BLA for aglatimagene (CAN-2409) in localized prostate cancer in Q4 2026.
Extended follow-up from Phase 2a NSCLC trial shows 50% of patients survived >24 months; Phase 3 NSCLC trial to start June 2026.
Announced commercial partnership with EVERSANA and $100M royalty funding agreement with RTW for potential launch.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Candel Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 14, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Candel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-222892

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.